East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Pembrolizumab
Keytruda
Routinely available
SMC (SMC2689)
28/05/2025

Indication

As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy. SMC restriction: adults whose tumours express programmed death-ligand 1 (PD-L1) with less than 50% (0 to 49%) tumou...

As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy. SMC restriction: adults whose tumours express programmed death-ligand 1 (PD-L1) with less than 50% (0 to 49%) tumour proportion score (TPS).

Therapeutic Area

Malignant disease and immunosuppression

Status Description

Routinely available in line with national guidance

Formulation

Concentrate for solution for infusion

Comments

Link to Advice

SMC2689

Advice Published

07/10/2024

SMC Submission Type

Full

SMC Status

Restricted